Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization

British Journal of Pharmacology

Volumn 171, Issue 21, 2014, Pages 4797-4807

  Sykes, David A ^a   Riddy, Darren M ^a   Stamp, Craig ^a   Bradley, Michelle E ^a   McGuiness, Neil ^a   Sattikar, Afrah ^a   Guerini, Danilo ^b   Rodrigues, Ines ^b   Glaenzel, Albrecht ^b   Dowling, Mark R ^a   Mullershausen, Florian ^b   Charlton, Steven J ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 [2 (4 OCTYLPHENYL)ETHYL] 1,3 PROPANEDIOL PHOSPHATE; BETA ARRESTIN; PROTEIN INHIBITOR; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; FTY 720P; LYSOPHOSPHOLIPID; ORGANOPHOSPHATE; RETINA S ANTIGEN; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HYDROLYSIS; INTERNALIZATION; LONGEVITY; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; RECEPTOR BINDING; UBIQUITINATION; ANALOGS AND DERIVATIVES; ANIMAL; CHO CELL LINE; CRICETULUS; KINETICS; METABOLISM;

ANIMALS; ARRESTINS; CHO CELLS; CRICETULUS; HUMANS; KINETICS; LYSOPHOSPHOLIPIDS; ORGANOPHOSPHATES; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84908321821     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12620     Document Type: Article

References (26)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. Bandhuvula P, Tam YY, Oskouian B, Saba JD (2005). The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J Biol Chem 280: 33697-33700.
3. Bradley ME, McGuinness N, Williams G, Charlton SJ, Dowling MR (2011). The in vitro metabolism of sphingosine-1-phosphate: identification, inhibition and pharmacological implications. Eur J Pharmacol 672: 56-61.
4. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G et al. (2010). Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 9: 883-897.
5. Chiba K, Matsuyuki H, Maeda Y, Sugahara K (2006). Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol 1: 11-19.
6. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X et al. (2010). Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415.
7. van Der Lee MM, Bras M, van Koppen CJ, Zaman GJ (2008). Beta-arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1. J Biomol Screen 13: 986-998.
8. Gurevich VV, Pals-Rylaarsdam R, Benovic JL, Hosey MM, Onorato JJ (1997). Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J Biol Chem 272: 28849-28852.
9. Jo E, Sanna MG, Gonzalez-Cabrera PJ, Thangada S, Tigyi G, Osborne DA et al. (2005). S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 12: 703-715.
10. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P et al. (2010). A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387-401.
11. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T et al. (2006). Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66: 221-231.
12. Le Stunff H, Mikami A, Giussani P, Hobson JP, Jolly PS, Milstien S et al. (2004). Role of sphingosine-1-phosphate phosphatase 1 in epidermal growth factor-induced chemotaxis. J Biol Chem 279: 34290-34297.
13. Lee CW, Choi JW, Chun J (2010). Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis. Arch Pharm Res 33: 1567-1574.
14. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V et al. (2004). Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355-360.
15. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K (2009). Persistent signaling induced by FTY720-phosphate is mediated by internalised S1P1 receptors. Nat Chem Biol 5: 428-434.
16. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR et al. (2007). Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 282: 9082-9089.
17. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y et al. (2007). Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 316: 295-298.
18. Riddy DM, Stamp C, Sykes DA, Charlton SJ, Dowling MR (2012). Reassessment of the pharmacology of Sphingosine-1-phosphate S1P3 receptor ligands using the DiscoveRx PathHunter™ and Ca2+ release functional assays. Br J Pharmacol 167: 868-880.
19. Sensken SC, Stäubert C, Keul P, Levkau B, Schöneberg T, Gräler MH (2008). Selective activation of G alpha i mediated signalling of S1P3 by FTY720-phosphate. Cell Signal 6: 1125-1133.
20. Sensken SC, Bode C, Graler MH (2009). Accumulation of fingolimod (FTY720) in lymphoid tissues contributes to prolonged efficacy. J Pharmacol Exp Ther 328: 963-969.
21. Shenoy SK, Lefkowitz RJ (2011). Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 32: 521-533.
22. Spiegel S, Milstien S (2003). Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4: 397-407.
23. Sykes DA, Charlton SC (2012). Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting 2-adrenoceptor agonists. Br J Pharmacol 165: 2672-2683.
24. Sykes DA, Dowling MR, Charlton SJ (2009). Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 76: 543-551.
25. Wei SH, Rosen H, Matheu MP, Sanna MG, Wang SK, Jo E et al. (2005). Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T-cells to lymphatic sinuses. Nat Immunol 6: 1228-1235.
26. Wetter JA, Revankar C, Hanson BJ (2009). Utilization of the Tango beta-arrestin recruitment technology for cell-based EDG receptor assay development and interrogation. J Biomol Screen 9: 1134-1141.